Provided by Tiger Fintech (Singapore) Pte. Ltd.

Protagonist Therapeutics

54.35
-0.1700-0.31%
Post-market: 54.350.00000.00%16:05 EDT
Volume:1.04M
Turnover:56.22M
Market Cap:3.34B
PE:12.85
High:54.54
Open:54.45
Low:52.43
Close:54.52
Loading ...

Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) — Best Biotech Stock for 2025?

Insider Monkey
·
Yesterday

Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025

ACCESS Newswire
·
18 Mar

Protagonist Therapeutics Is Maintained at Buy by Truist Securities

Dow Jones
·
12 Mar

PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study

Zacks
·
12 Mar

Wedbush Adjusts Protagonist Therapeutics Price Target to $70 From $58, Maintains Outperform Rating

MT Newswires Live
·
11 Mar

Protagonist Therapeutics Inc : Wedbush Raises Target Price to $70 From $58

THOMSON REUTERS
·
11 Mar

Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success

GuruFocus.com
·
11 Mar

Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday

Insider Monkey
·
11 Mar

Protagonist Therapeutics price target raised to $80 from $54 at H.C. Wainwright

TIPRANKS
·
11 Mar

Top Midday Gainers

MT Newswires Live
·
11 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Willis Lease Finance, CME Group

Reuters
·
11 Mar

Protagonist Therapeutics Inc : Btig Raises Target Price to $82 From $73

THOMSON REUTERS
·
10 Mar

Truist Securities Adjusts Price Target on Protagonist Therapeutics to $76 From $60, Keeps Buy Rating

MT Newswires Live
·
10 Mar

Protagonist Therapeutics Shares Rise After Positive Trial Data for Icotronkinra

Dow Jones
·
10 Mar

BUZZ-Protagonist Therapeutics rises as bowel disease drug succeeds mid-stage study

Reuters
·
10 Mar

Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out

Blockhead
·
10 Mar